Biotech Catalyst Calendar
37 upcoming clinical catalysts · sorted by expected readout
Upcoming readouts
2026
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2026-12 | BEAM | — | Recruiting | Sickle Cell Trait |
| 2026-12 | BEAM | PHASE1, PHASE2 | Active | Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia |
2027
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2027-05-19 | CRNA.OL | PHASE1, PHASE2 | Recruiting | Multiple Myeloma, Smoldering Multiple Myeloma |
| 2027-06 | CRSP | PHASE1 | Recruiting | Cardiovascular, Metabolic Disease, Dyslipidemias |
| 2027-06 | CRNA.OL | PHASE2 | Active | Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer |
| 2027-06-06 | CRSP | PHASE3 | Active | Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance |
| 2027-06-09 | VRTX | PHASE3 | Recruiting | Beta-Thalassemia, Thalassemia, Hematologic Diseases |
| 2027-06-30 | VRTX | PHASE3 | Recruiting | Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia |
| 2027-07 | NTLA | PHASE3 | Recruiting | Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease |
| 2027-07-22 | VRTX | PHASE2 | Active | Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| 2027-09-30 | VRTX | PHASE3 | Active | Cystic Fibrosis |
| 2027-11-14 | CRSP | PHASE3 | Active | Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn |
| 2027-12 | NTLA | PHASE3 | Recruiting | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| 2027-12-28 | VRTX | PHASE4 | Enrolling | Pain, Acute Postoperative, Breast Disease |
| 2027-12-30 | BEAM | PHASE1, PHASE2 | Recruiting | Glycogen Storage Disease Type Ia |
2028
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2028-02 | BEAM | PHASE1, PHASE2 | Active | Sickle Cell Disease |
| 2028-05 | BEAM | PHASE1, PHASE2 | Recruiting | Alpha 1-Antitrypsin Deficiency |
| 2028-06-02 | VRTX | PHASE2, PHASE3 | Recruiting | Proteinuric Kidney Disease |
| 2028-07-01 | CRSP | PHASE1, PHASE2 | Recruiting | Hypertension |
| 2028-08 | VRTX | PHASE4 | Upcoming | Knee Arthritis, Knee Osteoarthritis |
| 2028-12-29 | VRTX | PHASE2, PHASE3 | Recruiting | Primary Membranous Nephropathy |
2029
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2029-01-30 | VRTX | PHASE2 | Enrolling | Myotonic Dystrophy Type 1 (DM1) |
| 2029-02-02 | CRNO-B.ST | PHASE2 | Upcoming | Pulmonary Arterial Hypertension |
| 2029-03-02 | VRTX | PHASE2 | Recruiting | Myasthenia Gravis, Generalized |
| 2029-05-30 | BEAM | PHASE1 | Recruiting | T-Cell Acute Lymphoblastic Leukemia/Lymphoma |
| 2029-07-30 | VRTX | PHASE3 | Enrolling | Cystic Fibrosis |
2030
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2030-01 | CRSP | PHASE1, PHASE2 | Recruiting | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy |
| 2030-06-30 | VRTX | PHASE3 | Active | Cystic Fibrosis |
2031
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2031-12-31 | CRSP | PHASE1 | Recruiting | SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis |
2032
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2032-12 | VRTX | — | Recruiting | DM1, Myotonic Dystrophy, Myotonic Dystrophy 1 |
2033
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2033-12 | CRSP | PHASE1, PHASE2 | Recruiting | Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia |
2034
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2034-08-14 | NTLA | PHASE1, PHASE2 | Recruiting | Hemophilia B |
2038
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2038-03 | NTLA | — | Enrolling | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis |
| 2038-08 | CRSP | — | Enrolling | Hematologic Malignancy, Solid Malignancy |
2039
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2039-09-30 | CRSP | PHASE3 | Enrolling | Beta-Thalassemia, Thalassemia, Sickle Cell Disease |
2040
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2040-04 | NTLA | — | Enrolling | Hereditary Angioedema |
2043
| Expected | Company | Phase | Status | Indication |
|---|---|---|---|---|
| 2043-02-12 | BEAM | — | Recruiting | Hemoglobinopathy, Sickle Cell Disease |